Smith & Nephew plc (NYSE: SNN) Stock Competitors & Peer Comparison

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ABT has a market cap of 177.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ABT trades at $102.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ABT's P/E ratio is 19.68. In terms of profitability, SNN's ROE is +0.12%, compared to ABT's ROE of +0.11%. Regarding short-term risk, SNN is less volatile compared to ABT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ABT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SNN's ROE is +0.12%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, SNN is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BSX-PA's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, MDT has a market cap of 118B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while MDT trades at $92.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas MDT's P/E ratio is 16.66. In terms of profitability, SNN's ROE is +0.12%, compared to MDT's ROE of +0.11%. Regarding short-term risk, SNN is less volatile compared to MDT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check MDT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SYK has a market cap of 105.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SYK trades at $275.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SYK's P/E ratio is 20.54. In terms of profitability, SNN's ROE is +0.12%, compared to SYK's ROE of +0.16%. Regarding short-term risk, SNN is less volatile compared to SYK. This indicates lower risk in terms of short-term price fluctuations for SNN.Check SYK's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BSX has a market cap of 64.5B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BSX trades at $43.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BSX's P/E ratio is 14.00. In terms of profitability, SNN's ROE is +0.12%, compared to BSX's ROE of +0.15%. Regarding short-term risk, SNN is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BSX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, EW has a market cap of 50.8B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while EW trades at $88.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas EW's P/E ratio is 32.69. In terms of profitability, SNN's ROE is +0.12%, compared to EW's ROE of +0.10%. Regarding short-term risk, SNN is less volatile compared to EW. This indicates lower risk in terms of short-term price fluctuations for SNN.Check EW's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, DXCM has a market cap of 33.7B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while DXCM trades at $89.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas DXCM's P/E ratio is 35.04. In terms of profitability, SNN's ROE is +0.12%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, SNN is less volatile compared to DXCM. This indicates lower risk in terms of short-term price fluctuations for SNN.Check DXCM's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, GEHC has a market cap of 29B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while GEHC trades at $64.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas GEHC's P/E ratio is 14.06. In terms of profitability, SNN's ROE is +0.12%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, SNN is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for SNN.Check GEHC's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PHG has a market cap of 24.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PHG trades at $24.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PHG's P/E ratio is 14.10. In terms of profitability, SNN's ROE is +0.12%, compared to PHG's ROE of +0.10%. Regarding short-term risk, SNN is less volatile compared to PHG. This indicates lower risk in terms of short-term price fluctuations for SNN.Check PHG's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ZBH has a market cap of 18.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ZBH trades at $95.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ZBH's P/E ratio is 11.25. In terms of profitability, SNN's ROE is +0.12%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SNN is less volatile compared to ZBH. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ZBH's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SNN's ROE is +0.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SNN is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for SNN.Check ABMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SNN's ROE is +0.12%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SNN is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for SNN.Check SWAV's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PEN has a market cap of 12.5B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PEN trades at $317.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PEN's P/E ratio is 82.93. In terms of profitability, SNN's ROE is +0.12%, compared to PEN's ROE of +0.11%. Regarding short-term risk, SNN is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for SNN.Check PEN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ALGN has a market cap of 10.7B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ALGN trades at $147.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ALGN's P/E ratio is 13.65. In terms of profitability, SNN's ROE is +0.12%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, SNN is less volatile compared to ALGN. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ALGN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BIO-B has a market cap of 10.6B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BIO-B trades at $385.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BIO-B's P/E ratio is -67.94. In terms of profitability, SNN's ROE is +0.12%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, SNN is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for SNN.Check BIO-B's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BIO has a market cap of 10.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BIO trades at $376.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BIO's P/E ratio is 40.53. In terms of profitability, SNN's ROE is +0.12%, compared to BIO's ROE of +0.03%. Regarding short-term risk, SNN is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BIO's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, GMED has a market cap of 10B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while GMED trades at $74.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas GMED's P/E ratio is 16.69. In terms of profitability, SNN's ROE is +0.12%, compared to GMED's ROE of +0.12%. Regarding short-term risk, SNN is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for SNN.Check GMED's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PODD has a market cap of 9.7B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PODD trades at $140.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PODD's P/E ratio is 23.95. In terms of profitability, SNN's ROE is +0.12%, compared to PODD's ROE of +0.27%. Regarding short-term risk, SNN is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check PODD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, GKOS has a market cap of 9.7B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while GKOS trades at $163.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas GKOS's P/E ratio is -190.27. In terms of profitability, SNN's ROE is +0.12%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, SNN is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check GKOS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas MASI's P/E ratio is 44.43. In terms of profitability, SNN's ROE is +0.12%, compared to MASI's ROE of +0.09%. Regarding short-term risk, SNN is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for SNN.Check MASI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BRKR has a market cap of 9.3B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BRKR trades at $61.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BRKR's P/E ratio is 30.85. In terms of profitability, SNN's ROE is +0.12%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, SNN is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BRKR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BRKRP has a market cap of 9B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BRKRP trades at $447.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BRKRP's P/E ratio is 245.01. In terms of profitability, SNN's ROE is +0.12%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, SNN is less volatile compared to BRKRP. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BRKRP's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, HAE has a market cap of 4.9B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while HAE trades at $108.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas HAE's P/E ratio is 21.66. In terms of profitability, SNN's ROE is +0.12%, compared to HAE's ROE of +0.11%. Regarding short-term risk, SNN is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for SNN.Check HAE's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NARI's P/E ratio is -59.24. In terms of profitability, SNN's ROE is +0.12%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SNN is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for SNN.Check NARI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ITGR trades at $126.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ITGR's P/E ratio is 19.90. In terms of profitability, SNN's ROE is +0.12%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, SNN is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for SNN.Check ITGR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, LIVN has a market cap of 4.3B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while LIVN trades at $78.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas LIVN's P/E ratio is 18.53. In terms of profitability, SNN's ROE is +0.12%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, SNN is less volatile compared to LIVN. This indicates lower risk in terms of short-term price fluctuations for SNN.Check LIVN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SNN's ROE is +0.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SNN is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for SNN.Check AXNX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while IRTC trades at $109.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas IRTC's P/E ratio is -254.26. In terms of profitability, SNN's ROE is +0.12%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, SNN is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for SNN.Check IRTC's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, TMDX has a market cap of 3B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while TMDX trades at $86.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas TMDX's P/E ratio is 43.87. In terms of profitability, SNN's ROE is +0.12%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, SNN is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check TMDX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NEOG trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NEOG's P/E ratio is 46.39. In terms of profitability, SNN's ROE is +0.12%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, SNN is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for SNN.Check NEOG's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AXGN has a market cap of 2.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AXGN trades at $44.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AXGN's P/E ratio is 116.39. In terms of profitability, SNN's ROE is +0.12%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, SNN is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for SNN.Check AXGN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, INSP has a market cap of 2.2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while INSP trades at $76.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas INSP's P/E ratio is 33.84. In terms of profitability, SNN's ROE is +0.12%, compared to INSP's ROE of +0.18%. Regarding short-term risk, SNN is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for SNN.Check INSP's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, UFPT has a market cap of 2.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while UFPT trades at $276.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas UFPT's P/E ratio is 28.26. In terms of profitability, SNN's ROE is +0.12%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, SNN is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check UFPT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BFLY has a market cap of 2.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BFLY trades at $7.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BFLY's P/E ratio is -32.81. In terms of profitability, SNN's ROE is +0.12%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, SNN is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BFLY's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SNN's ROE is +0.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SNN is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for SNN.Check NUVA's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ESTA trades at $69.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ESTA's P/E ratio is -55.00. In terms of profitability, SNN's ROE is +0.12%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, SNN is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ESTA's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NVCR trades at $16.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NVCR's P/E ratio is -12.84. In terms of profitability, SNN's ROE is +0.12%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, SNN is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for SNN.Check NVCR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ATEC trades at $10.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ATEC's P/E ratio is -169.67. In terms of profitability, SNN's ROE is +0.12%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, SNN is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ATEC's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CNMD trades at $45.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CNMD's P/E ratio is 10.00. In terms of profitability, SNN's ROE is +0.12%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, SNN is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CNMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SNN's ROE is +0.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SNN is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for SNN.Check HSKA's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, IART has a market cap of 1.2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while IART trades at $15.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas IART's P/E ratio is 6.45. In terms of profitability, SNN's ROE is +0.12%, compared to IART's ROE of -0.01%. Regarding short-term risk, SNN is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for SNN.Check IART's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AVNS's P/E ratio is 27.77. In terms of profitability, SNN's ROE is +0.12%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, SNN is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for SNN.Check AVNS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while TNDM trades at $16.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas TNDM's P/E ratio is -18.14. In terms of profitability, SNN's ROE is +0.12%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, SNN is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for SNN.Check TNDM's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AORT trades at $23.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AORT's P/E ratio is 38.85. In terms of profitability, SNN's ROE is +0.12%, compared to AORT's ROE of -0.01%. Regarding short-term risk, SNN is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check AORT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SILK's P/E ratio is -18.96. In terms of profitability, SNN's ROE is +0.12%, compared to SILK's ROE of -0.35%. Regarding short-term risk, SNN is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for SNN.Check SILK's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas FNA's P/E ratio is -19.83. In terms of profitability, SNN's ROE is +0.12%, compared to FNA's ROE of -0.35%. Regarding short-term risk, SNN is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for SNN.Check FNA's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PRCT trades at $19.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PRCT's P/E ratio is -9.95. In terms of profitability, SNN's ROE is +0.12%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, SNN is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check PRCT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while LMRI trades at $11.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas LMRI's P/E ratio is -21.56. In terms of profitability, SNN's ROE is +0.12%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, SNN is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for SNN.Check LMRI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, IRMD has a market cap of 1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while IRMD trades at $82.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas IRMD's P/E ratio is 41.27. In terms of profitability, SNN's ROE is +0.12%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, SNN is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check IRMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ENOV has a market cap of 1B. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ENOV trades at $18.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ENOV's P/E ratio is 5.17. In terms of profitability, SNN's ROE is +0.12%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, SNN is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ENOV's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BBNX has a market cap of 984.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BBNX trades at $21.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BBNX's P/E ratio is -13.27. In terms of profitability, SNN's ROE is +0.12%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, SNN is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BBNX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CBLL has a market cap of 924.7M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CBLL trades at $24.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CBLL's P/E ratio is -13.85. In terms of profitability, SNN's ROE is +0.12%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, SNN is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CBLL's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BVS has a market cap of 874.6M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BVS trades at $12.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BVS's P/E ratio is 16.99. In terms of profitability, SNN's ROE is +0.12%, compared to BVS's ROE of +0.28%. Regarding short-term risk, SNN is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BVS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CSII's P/E ratio is -20.83. In terms of profitability, SNN's ROE is +0.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SNN is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for SNN.Check CSII's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, INMD has a market cap of 824.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while INMD trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas INMD's P/E ratio is 9.97. In terms of profitability, SNN's ROE is +0.12%, compared to INMD's ROE of +0.12%. Regarding short-term risk, SNN is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check INMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SIBN has a market cap of 802.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SIBN trades at $18.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SIBN's P/E ratio is -53.21. In terms of profitability, SNN's ROE is +0.12%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, SNN is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for SNN.Check SIBN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AVR has a market cap of 793.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AVR trades at $8.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AVR's P/E ratio is -4.21. In terms of profitability, SNN's ROE is +0.12%, compared to AVR's ROE of -0.78%. Regarding short-term risk, SNN is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for SNN.Check AVR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, VREX has a market cap of 778.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while VREX trades at $18.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas VREX's P/E ratio is 19.46. In terms of profitability, SNN's ROE is +0.12%, compared to VREX's ROE of +0.05%. Regarding short-term risk, SNN is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for SNN.Check VREX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, AHCO has a market cap of 776.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while AHCO trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas AHCO's P/E ratio is 11.65. In terms of profitability, SNN's ROE is +0.12%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, SNN is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for SNN.Check AHCO's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CTKB has a market cap of 684.5M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CTKB trades at $5.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CTKB's P/E ratio is -28.08. In terms of profitability, SNN's ROE is +0.12%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, SNN is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CTKB's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SSII has a market cap of 652.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SSII trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SSII's P/E ratio is -63.58. In terms of profitability, SNN's ROE is +0.12%, compared to SSII's ROE of -0.27%. Regarding short-term risk, SNN is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for SNN.Check SSII's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SRDX's P/E ratio is -34.66. In terms of profitability, SNN's ROE is +0.12%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, SNN is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for SNN.Check SRDX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas APEN's P/E ratio is -9.43. In terms of profitability, SNN's ROE is +0.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SNN is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for SNN.Check APEN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, KIDS has a market cap of 560.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while KIDS trades at $21.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas KIDS's P/E ratio is -18.49. In terms of profitability, SNN's ROE is +0.12%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, SNN is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check KIDS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, DCTH has a market cap of 556.1M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while DCTH trades at $16.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas DCTH's P/E ratio is 1611.00. In terms of profitability, SNN's ROE is +0.12%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, SNN is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for SNN.Check DCTH's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SNN's ROE is +0.12%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, SNN is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for SNN.Check ZIMV's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CERS has a market cap of 534M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CERS trades at $2.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CERS's P/E ratio is -52.89. In terms of profitability, SNN's ROE is +0.12%, compared to CERS's ROE of -0.10%. Regarding short-term risk, SNN is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CERS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, TCMD has a market cap of 500.7M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while TCMD trades at $22.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas TCMD's P/E ratio is 20.56. In terms of profitability, SNN's ROE is +0.12%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, SNN is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check TCMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NPCE has a market cap of 486.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NPCE trades at $14.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NPCE's P/E ratio is -25.05. In terms of profitability, SNN's ROE is +0.12%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, SNN is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for SNN.Check NPCE's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SGHT has a market cap of 436.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SGHT trades at $8.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SGHT's P/E ratio is -14.32. In terms of profitability, SNN's ROE is +0.12%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, SNN is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check SGHT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PACB has a market cap of 425.5M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PACB trades at $1.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PACB's P/E ratio is -3.34. In terms of profitability, SNN's ROE is +0.12%, compared to PACB's ROE of -49.62%. Regarding short-term risk, SNN is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for SNN.Check PACB's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CLPT has a market cap of 414.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CLPT trades at $13.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CLPT's P/E ratio is -11.72. In terms of profitability, SNN's ROE is +0.12%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, SNN is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CLPT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SENS has a market cap of 400.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SENS trades at $9.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SENS's P/E ratio is -4.30. In terms of profitability, SNN's ROE is +0.12%, compared to SENS's ROE of -1.66%. Regarding short-term risk, SNN is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check SENS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, OFIX has a market cap of 352.1M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while OFIX trades at $8.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas OFIX's P/E ratio is -5.67. In terms of profitability, SNN's ROE is +0.12%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, SNN is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check OFIX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CV has a market cap of 334.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CV trades at $6.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CV's P/E ratio is -10.63. In terms of profitability, SNN's ROE is +0.12%, compared to CV's ROE of -1.78%. Regarding short-term risk, SNN is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CV's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, CATX has a market cap of 327.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while CATX trades at $2.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas CATX's P/E ratio is -2.16. In terms of profitability, SNN's ROE is +0.12%, compared to CATX's ROE of -0.42%. Regarding short-term risk, SNN is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check CATX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, TLSI has a market cap of 314M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while TLSI trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas TLSI's P/E ratio is -3.04. In terms of profitability, SNN's ROE is +0.12%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, SNN is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for SNN.Check TLSI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SNN's ROE is +0.12%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, SNN is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for SNN.Check SMLR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, TMCI has a market cap of 291.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while TMCI trades at $4.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas TMCI's P/E ratio is -4.78. In terms of profitability, SNN's ROE is +0.12%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, SNN is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for SNN.Check TMCI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, RCEL has a market cap of 273.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while RCEL trades at $11.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas RCEL's P/E ratio is -7.65. In terms of profitability, SNN's ROE is +0.12%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, SNN is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for SNN.Check RCEL's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, INFU has a market cap of 258.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while INFU trades at $12.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas INFU's P/E ratio is 31.22. In terms of profitability, SNN's ROE is +0.12%, compared to INFU's ROE of +0.15%. Regarding short-term risk, SNN is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for SNN.Check INFU's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas MGRM's P/E ratio is -12.00. In terms of profitability, SNN's ROE is +0.12%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, SNN is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for SNN.Check MGRM's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SNN's ROE is +0.12%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, SNN is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for SNN.Check NVRO's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ELMD has a market cap of 218.5M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ELMD trades at $26.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ELMD's P/E ratio is 20.15. In terms of profitability, SNN's ROE is +0.12%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, SNN is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ELMD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, RXST has a market cap of 215.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while RXST trades at $5.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas RXST's P/E ratio is -4.60. In terms of profitability, SNN's ROE is +0.12%, compared to RXST's ROE of -0.17%. Regarding short-term risk, SNN is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for SNN.Check RXST's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, PROF has a market cap of 212.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while PROF trades at $5.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas PROF's P/E ratio is -5.98. In terms of profitability, SNN's ROE is +0.12%, compared to PROF's ROE of -0.56%. Regarding short-term risk, SNN is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for SNN.Check PROF's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, STIM has a market cap of 201.8M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while STIM trades at $2.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas STIM's P/E ratio is -6.59. In terms of profitability, SNN's ROE is +0.12%, compared to STIM's ROE of -1.51%. Regarding short-term risk, SNN is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for SNN.Check STIM's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SNN's ROE is +0.12%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, SNN is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for SNN.Check BSGM's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SNN's ROE is +0.12%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SNN is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for SNN.Check MDGS's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas QIPT's P/E ratio is -15.87. In terms of profitability, SNN's ROE is +0.12%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SNN is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for SNN.Check QIPT's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while FOCL trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas FOCL's P/E ratio is -4.01. In terms of profitability, SNN's ROE is +0.12%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, SNN is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for SNN.Check FOCL's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, LUCD has a market cap of 149.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while LUCD trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas LUCD's P/E ratio is -2.12. In terms of profitability, SNN's ROE is +0.12%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, SNN is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for SNN.Check LUCD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, QSI has a market cap of 147.4M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while QSI trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas QSI's P/E ratio is -1.62. In terms of profitability, SNN's ROE is +0.12%, compared to QSI's ROE of -0.47%. Regarding short-term risk, SNN is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for SNN.Check QSI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, QTRX has a market cap of 144.6M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while QTRX trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas QTRX's P/E ratio is -1.21. In terms of profitability, SNN's ROE is +0.12%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, SNN is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for SNN.Check QTRX's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, INGN has a market cap of 139.2M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while INGN trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas INGN's P/E ratio is -5.65. In terms of profitability, SNN's ROE is +0.12%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SNN is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for SNN.Check INGN's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ICAD's P/E ratio is -20.37. In terms of profitability, SNN's ROE is +0.12%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, SNN is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for SNN.Check ICAD's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ECOR has a market cap of 105.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ECOR trades at $11.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ECOR's P/E ratio is -6.95. In terms of profitability, SNN's ROE is +0.12%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, SNN is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ECOR's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas HJLI's P/E ratio is N/A. In terms of profitability, SNN's ROE is +0.12%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, SNN is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for SNN.Check HJLI's competition here

Smith & Nephew plc (NYSE: SNN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SNN stands at 11.6B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, SNN is priced at $27.56 on the NYSE, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SNN currently has a P/E ratio of 12.97, whereas ASXC's P/E ratio is -1.12. In terms of profitability, SNN's ROE is +0.12%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, SNN is less volatile compared to ASXC. This indicates lower risk in terms of short-term price fluctuations for SNN.Check ASXC's competition here